Xeljanz

 

Topic mentions per year

Topic mentions per year

2013-2017
02420132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Treatment of Alopecia AreataWith Tofacitinib Tofacitinib citrate is a Janus kinase 1/3 inhibitor approved for the treatment of… (More)
Is this relevant?
Review
2017
Review
2017
  • Drug and therapeutics bulletin
  • 2017
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that causes inflammation and destruction of the joints.1-3… (More)
Is this relevant?
2015
2015
A high-performance liquid chromatography (HPLC) method was established to detect Xeljanz enantiomers in active pharmaceutical… (More)
Is this relevant?
Review
2014
Review
2014
Following on the heels of the US FDA approval of tofacitinib (Xeljanz, Pfizer, USA), an inhibitor of the JAK family members, and… (More)
Is this relevant?
2014
2014
In the last 15 years, the therapeutical options for the treatment of chronic inflammatory diseases in rheumatology have increased… (More)
Is this relevant?
2013
2013
On November 6, two weeks ahead of deadline, the US Food and Drug Administration (FDA) approved the first Janus kinase (JAK… (More)
Is this relevant?
2013
2013
volume 31 number 1 january 2013 nature biotechnology who are resistant or refractory to other available drugs,” Crofford adds… (More)
Is this relevant?
Review
2013
Review
2013
After two decades of research and development activity focussed on orally active kinase inhibitors, the first such drug (the JAK… (More)
Is this relevant?
Review
2013
Review
2013
  • The Medical letter on drugs and therapeutics
  • 2013
 
Is this relevant?
Review
2013
Review
2013
INTRODUCTION Janus kinases (JAKs) comprise a family of four enzymes, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), centrally… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?